EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Impact of asymptomatic bacteriuria on the outcomes and tolerability of Bacillus Calmette–Guérin immunotherapy

Antti Nummi, Pertti Nurminen, Olli Kesti, Mikael Högerman, Otto Ettala, Peter J Boström, Antti Kaipia, Jukka Sairanen, Riikka Järvinen

Scandinavian Journal of Urology · 24.04.2026 · 61 · 148-155

DOI: 10.2340/sju.v61.45539 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Scandinavian Journal of Urology, online erschienen am 24.04.2026. Verfasst von Antti Nummi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Helsinki University Hospital, Helsinki, Finland. antti.nummi@hus.fi. Hauptthemen laut MEDLINE: BCG Vaccine, Bacteriuria, Immunotherapy, Adjuvants, Immunologic. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To determine whether asymptomatic bacteriuria (ABU) prior to Bacillus Calmette-Guérin (BCG) immunotherapy has an impact on the oncological results and overall tolerability of BCG treatment in patients with non-muscle-invasive bladder cancer (NMIBC). Materials and methods: We analyzed retrospectively all patients who received ≥ 1 BCG instillations as treatment of NMIBC in Helsinki University Hospital and Turku University Hospital during 2009–2018. Patients submitted urine specimen 1–7 days prior to the initiation of BCG therapy. ABU was classified as having any positive urine culture but no dysuria or fever. Our primary endpoints were 5-yr recurrence-free survival and progression-free survival. Discontinuation rate of BCG therapy was a secondary endpoint.

Results

We identified 795 patients, of whom 154 (19%) had ABU prior to the first BCG instillation. The 5-yr recurrence-free survival rates in the uninfected and bacteriuric groups were 63% (95% confidence interval [CI]: 59–67%) vs. 69% (95% CI: 62–78%), respectively (hazard ratio [HR] 0.83, 95% CI 0.60–1.14). The 5-yr progression-free survival rates were 88% (95% CI: 86–90%) vs. 89% (95% CI: 84–94%), respectively (HR 0.86, 95% CI 0.50–1.49). The 3-yr discontinuation-free survival rates were 51% (95% CI: 47–54%) vs. 51% (95% CI: 44–60%), respectively (HR 0.98, 95% CI 0.75–1.28).

Conclusion

ABU did not significantly affect BCG immunotherapy outcomes. Intravesical BCG during ABU is safe, with similar discontinuation rates, indicating very similar treatment tolerability.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BCG VaccineBacteriuriaImmunotherapyAdjuvants, ImmunologicUrinary Bladder NeoplasmsAsymptomatic InfectionsHumansMaleFemaleRetrospective StudiesNon-Muscle Invasive Bladder NeoplasmsAgedTreatment OutcomeMiddle AgedAdministration, IntravesicalProgression-Free Survival

Substanzen

BCG VaccineAdjuvants, Immunologic

Autor:innen und Institutionen

  • Department of Urology, Helsinki University Hospital, Helsinki, Finland. antti.nummi@hus.fi.
  • Department of Urology, Turku University Hospital, Turku, Finland.
  • Department of Urology, Tampere University Hospital, Tampere, Finland.
  • Department of Urology, Helsinki University Hospital, Helsinki, Finland.

Zitieren

APA

Nummi, A., Nurminen, P., Kesti, O., Högerman, M., Ettala, O., Boström, P. J., Kaipia, A., Sairanen, J., & Järvinen, R. (2026). Impact of asymptomatic bacteriuria on the outcomes and tolerability of Bacillus Calmette–Guérin immunotherapy. Scandinavian Journal of Urology, 61, 148-155. https://doi.org/10.2340/sju.v61.45539

Vancouver

Nummi A, Nurminen P, Kesti O, Högerman M, Ettala O, Boström PJ, et al. Impact of asymptomatic bacteriuria on the outcomes and tolerability of Bacillus Calmette–Guérin immunotherapy. Scandinavian Journal of Urology. 2026;61:148-155. doi:10.2340/sju.v61.45539

BibTeX
@article{Nummi2026,
  author = {Nummi, Antti and Nurminen, Pertti and Kesti, Olli and Högerman, Mikael and Ettala, Otto and Boström, Peter J and Kaipia, Antti and Sairanen, Jukka and Järvinen, Riikka},
  title = {Impact of asymptomatic bacteriuria on the outcomes and tolerability of Bacillus Calmette–Guérin immunotherapy},
  journal = {Scandinavian Journal of Urology},
  year = {2026},
  volume = {61},
  pages = {148--155},
  doi = {10.2340/sju.v61.45539}
}
Kostenlos starten →